XTX Topco’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
– Sell
-10,053
Closed -$290 – 3397
2025
Q1
$290 Sell
10,053
-71,407
-88% -$12K ﹤0.01% 2329
2024
Q4
$18.7K Buy
81,460
+52,626
+183% +$63.2K ﹤0.01% 2053
2024
Q3
$62K Buy
+28,834
New +$104K ﹤0.01% 1665
2024
Q2
– Sell
-10,949
Closed -$58.6K – 2587
2024
Q1
$58.6K Sell
10,949
-57
-0.5% -$394 0.01% 1448
2023
Q4
$85.7K Buy
+11,006
New +$37.7K 0.02% 1146
2022
Q2
– Sell
-4,456
Closed -$53K – 1157
2022
Q1
$53K Buy
4,456
+3,304
+287% +$59.1K 0.02% 586
2021
Q4
$38K Buy
+1,152
New +$46.6K 0.02% 591
2021
Q3
– Sell
-2,602
Closed -$142K – 1126
2021
Q2
$142K Buy
2,602
+1,485
+133% +$87.9K 0.05% 613
2021
Q1
$84K Buy
+1,117
New +$116K 0.04% 580

XTX Topco's SYRS Position: Q2 2025 in Review

XTX Topco sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2025, closing a stake of 10,053 shares — an estimated $290 sold.

XTX Topco first reported a position in SYRS in Q1 2021 and held it in 9 quarters. The position peaked at $142K in Q2 2021. 0 funds tracked by Wall St. Rank hold SYRS as of Q2 2025.

  • XTX Topco reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2025 after selling out during the quarter.
  • XTX Topco sold 10,053 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2025, an estimated $290.
  • XTX Topco first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 9 quarters.
  • XTX Topco's Syros Pharmaceuticals, Inc. Common Stock position peaked at $142K in Q2 2021.
  • 0 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2025.

Based on XTX Topco's 13F filing for Q2 2025, filed 12 Aug 2025.